ArticleEuropean journal of medical research2025
Investigating the potential role of EIF2S2 in OSCC progression through comprehensive bioinformatics analysis and experimental validation.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe expression of EIF2S2 in oral squamous cell carcinoma (OSCC) may be closely linked to tumor progression and immune evasion.
objectiveTo explore the expression patterns of EIF2S2 in OSCC and its associations with the immune microenvironment, mutational burden, drug sensitivity, and prognosis.
methodsWe studied the functionality of EIF2S2 through tissue sample analysis, differential expression analysis, single-cell RNA-sequencing (scRNA-seq), immune scoring, drug sensitivity assessments, and interaction network construction.
resultsEIF2S2 expression was significantly upregulated in OSCC tissues (AUC = 0.846). There were notable differences in immune scoring, cell infiltration, and functional activity between high and low expression groups. The high expression group exhibited significantly reduced immune cell infiltration (e.g., CD8 + T cells), decreased immune function, and poor responses to CTLA-4 and PD-1 therapies. At the single-cell level, significant changes were observed in the ratios of B cells and T cells in the high expression group. Differential gene analysis revealed significant differences in immune-related genes between the two groups. Mutational analysis showed a higher tumor mutational burden (TMB) in the high EIF2S2 expression group, which correlated with worse prognosis (p = 0.012). Drug enrichment analysis identified several potential drugs associated with EIF2S2, with molecular docking confirming binding patterns.
conclusionEIF2S2 not only promotes tumor progression in OSCC, but may also affect the efficacy of immunotherapy by modulating the immune microenvironment, with its high expression correlating with poor prognosis, suggesting that EIF2S2 may serve as a potential biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.